Physician

David Edward Houser, MD

According to 2025 Medicare claims, David Houser, MD (NPI: 1629344064) practices nephrology in the Peoria, IL market, with the plurality of this provider's patient population coming from Peoria, IL. This provider's primary affiliated billing organization is RENALCARE ASSOCIATES, S.C. (NPI: 1649300377; TIN: 370995483) and primary practice location at 61603-3168. Houser is affiliated with the OSF Healthcare System (ACO ID: A3289) and SBL accountable care organization (ACO ID: A5147), participating under the MSSP model.

Houser's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 822 traditional Medicare patients, billed 2,722 HCPCS/CPT codes, and received $195,948 in Medicare payments. The top billing code was 99223 (Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes). Part D data shows 1,635 prescription claims across 260 beneficiaries totaling $91,441 in drug costs, led by Veltassa (Patiromer Calcium Sorbitex). DME data shows 338 claims. No Open Payments records. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing did not follow a clear longitudinal pattern. Concurrently, Part D prescription costs have moved up and down with repeated peaks and valleys, starting at $6,399 and ending at $91,441. In contrast, DME billing represents a smaller volume and changed little.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	316	1,034	$106,037
2018	841	2,919	$257,089
2019	912	3,417	$268,995
2020	882	2,849	$247,136
2021	781	2,256	$252,098
2022	747	2,013	$220,772
2023	796	1,979	$184,824
2024	822	2,722	$195,948

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	17	46	$6,399
2016	N/R	N/R	N/R
2017	24	98	$1,710
2018	129	540	$36,432
2019	189	986	$95,025
2020	188	1,274	$146,945
2021	197	1,224	$75,635
2022	185	1,121	$44,214
2023	204	1,135	$50,373
2024	260	1,635	$91,441

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	131	$5,434
2020	N/R	193	$13,695
2021	N/R	143	$7,154
2022	N/R	201	$7,618
2023	N/R	302	$9,343
2024	N/R	338	$8,479

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99223	Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes	125	135	$126
99233	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes	163	450	$90
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	104	238	$59
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	453	656	$58
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	498	739	$11

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Veltassa	Patiromer Calcium Sorbitex	22	754	$23,933
Jardiance	Empagliflozin	17	810	$15,902
Cyclosporine Modified	Cyclosporine, Modified	18	780	$5,272
Mycophenolate Mofetil	Mycophenolate Mofetil	15	730	$3,416
Potassium Citrate Er	Potassium Citrate	31	1,280	$2,742

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J7518	Mycophenolic acid, oral, 180 mg	N	N/R	50	$3,443
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	83	$1,506
J7515	Cyclosporine, oral, 25 mg	N	N/R	12	$1,193
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	86	$1,066
J7517	Mycophenolate mofetil, oral, 250 mg	N	N/R	29	$745

Open Payments Summary

No connected Open Payments records were found for this physician in General Payments, Research Payments, or Ownership / Investment Interests.

Explore More Providers

FAQ

What Medicare data is available for David Edward Houser, MD?

Tedicare shows public-source Medicare data for David Edward Houser, MD (NPI 1629344064), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does David Edward Houser, MD have ACO affiliation data?

David Edward Houser, MD is shown with ACO affiliation data for OSF Healthcare System (MSSP, ACO ID A3289) and SBL accountable care organization (MSSP, ACO ID A5147).

What billing organization is linked to David Edward Houser, MD?

David Edward Houser, MD is linked to RENALCARE ASSOCIATES, S.C. (billing NPI 1649300377) in the available physician profile data.

Does David Edward Houser, MD have Open Payments data?

No connected Open Payments records are shown for this physician in the available General Payments, Research Payments, or Ownership / Investment Interests data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.